Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company that regularly issues updates on its cardiac monitoring platform, regulatory milestones, and commercialization plans. Company news highlights its focus on transforming cardiac care through portable, cable-free ECG technologies that can be used by adult patients in clinical settings or at home for arrhythmia assessment.
News releases frequently cover developments related to HeartBeam’s 3D ECG technology and 12-lead ECG synthesis software. These include FDA 510(k) clearance for arrhythmia assessment, the regulatory path for the 12-lead synthesis software, and the company’s responses to a Not Substantially Equivalent (NSE) decision and subsequent successful appeal. Investors can also find updates on clinical studies such as the VALID-ECG study and deep learning research presented at conferences like HRX Live, which examine how HeartBeam’s algorithms perform in detecting atrial fibrillation, atrial flutter, and sinus rhythm.
HeartBeam’s news flow also addresses commercial readiness, including plans for limited U.S. launch with concierge and preventive cardiology practices, establishment of a cardiology reader service, and infrastructure for customer service, contract manufacturing, and logistics. Announcements about the partnership with HeartNexus, Inc. describe how synthesized 12-lead ECGs from HeartBeam’s system will be reviewed by a network of board-certified cardiologists, supporting arrhythmia assessment and patient triage outside traditional healthcare facilities.
In addition, periodic earnings releases and conference participation notices provide insight into the company’s operating expenses, cash position, and engagement with investors and industry partners. Visitors to this news page can review these updates to understand how HeartBeam is progressing on regulatory, clinical, and commercialization objectives for its cardiac monitoring technologies.
HeartBeam, Inc. (NASDAQ: BEAT) announces a conference call on May 12, 2022 at 4:30 p.m. Eastern time, to discuss its first-quarter results for the period ending March 31, 2022. The call will feature CEO Branislav Vajdic, CFO Richard Brounstein, and CBO Jon Hunt. Participants can join via telephone or webcast. A replay will be available until July 12, 2022. HeartBeam specializes in digital healthcare technology for heart attack detection using an innovative ECG device. For further details, visit www.heartbeam.com.
HeartBeam, Inc. (NASDAQ: BEAT) announced a virtual roadshow webinar scheduled for April 27, 2022, at 11:30 a.m. Eastern Time. The event will feature CEO Branislav Vajdic, CFO Richard Brounstein, and CBO Jon Hunt discussing recent company announcements and key milestones for 2022. Participants can join via a provided webcast link or dial-in numbers. A replay will be available for two months post-event. HeartBeam focuses on innovative ECG telemedicine technology aimed at enhancing heart attack detection for high-risk patients outside medical facilities.
HeartBeam, a digital healthcare company focused on ECG telemedicine for heart attack detection, announced significant progress for Q4 2021, including partnerships for its Emergency Department (ED) myocardial infarction software and telehealth solutions. Key highlights include a $14.9 million IPO, new partnerships with LIVMOR Inc. and Phoebe Putney Health System, and an experienced leadership team poised for commercialization. The company ended 2021 with $13.2 million in cash, projecting sufficient funds into 2023, aiming for FDA submissions in 2022 and 2023.
HeartBeam, Inc. (NASDAQ: BEAT) has entered a professional services agreement with Triple Ring Technologies for the development of a Telehealth 3D vector ECG collection device aimed at remote heart attack monitoring. This partnership will span five phases and is scheduled for FDA 510k submission in Q4 2022. The device is designed for patient use at home, providing crucial ECG data to physicians in real-time. With over 18 million people in the U.S. suffering from coronary artery disease, this innovative solution addresses a significant need in cardiac care.
HeartBeam, Inc. (NASDAQ: BEAT) will conduct a conference call on March 24, 2022, at 4:30 p.m. Eastern time to discuss its fourth quarter and full-year results for fiscal 2021, ending December 31, 2021. The call will feature CEO Branislav Vajdic, CFO Richard Brounstein, and CBO Jon Hunt. A press release with results will precede the call. Interested parties can join via phone or webcast. A telephone replay will be available until June 24, 2022. HeartBeam focuses on innovative ECG technology for heart attack detection.
HeartBeam, Inc. (NASDAQ: BEAT) has announced a Business Associate Agreement and Clinical Trial Agreement with Phoebe Putney Health System to conduct a pilot study of HeartBeam’s Myocardial Infarction software product. This partnership aims to evaluate the software’s effectiveness in detecting heart attacks in emergency settings. HeartBeam will conduct additional studies and pursue future scientific and commercial collaborations, enhancing its position in the telehealth space for remote heart attack detection.
HeartBeam, Inc. (NASDAQ: BEAT) has announced a partnership with LIVMOR Inc. to develop a HeartBeam branded version of LIVMOR's FDA-cleared Halo+ Remote Patient Monitoring (RPM) platform. This collaboration aims to enhance heart attack detection by customizing the platform for HeartBeam's products. CEO Branislav Vajdic emphasized that using LIVMOR's established platform will expedite the FDA submission of their heart attack detection software, aimed at Emergency Department settings, later this year. This partnership aims to improve the accuracy of myocardial infarction detection.
HeartBeam, Inc. (NASDAQ: BEAT) has established a Scientific Advisory Board (SAB) to enhance its medical studies and product development. The board will be chaired by C. Michael Gibson, an esteemed cardiologist known for his work in cardiovascular research. Dr. Gibson's extensive experience includes leading over 120 clinical trials and contributing to major cardiac drug approvals. This strategic move aims to bolster HeartBeam's proprietary ECG telemedicine technology, focusing on accurate heart attack diagnosis in ambulatory settings.
HeartBeam, Inc. (NASDAQ: BEAT), a digital healthcare company, announced its participation in the H.C. Wainwright BIOCONNECT Conference from January 10-13, 2022. Key executives, including CEO Branislav Vajdic, will conduct video meetings during the event. The conference aims to showcase HeartBeam's innovative ECG telemedicine technology, designed to diagnose cardiovascular diseases effectively outside traditional medical settings. This breakthrough technology targets a significant market need, particularly in diagnosing heart attacks in high-risk patients.
HeartBeam, Inc. (NASDAQ: BEAT) has appointed Alan Baumel as the new Chief Operating Officer, a role focused on product development and regulatory affairs for their innovative ECG telemedicine technology. With over 35 years in the medical device sector, Baumel is expected to enhance HeartBeam's commercialization strategy and accelerate FDA product development. His experience includes leadership roles at Bardy Diagnostics and contributions to improving medical device quality and safety. HeartBeam aims to address significant needs in heart attack detection outside medical institutions.